Article
Classes of ITD predict outcomes in patients with AML treated with <i>FLT3</i> inhibitors
2018-05-14
Abstract excerpt
Recurrent internal tandem duplication (ITD) mutations are observed in various cancers including acute myeloid leukemia (AML). ITD mutations of Fms-like tyrosine kinase 3 ( FLT3 ) receptor increase kinase activity, and are associated with poor prognostic outcomes. Currently, several small-molecule FLT3 inhibitors (FLT3i) are in clinical trials for targeted therapy of high-risk FLT3-ITD-positive AML. However, the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 031cb267-8fba-56f8-b9c3-cb2de0ed04fc
- DOI
- 10.1101/322354
